gatifloxacin has been researched along with Body Weight in 3 studies
Gatifloxacin: A fluoroquinolone antibacterial agent and DNA TOPOISOMERASE II inhibitor that is used as an ophthalmic solution for the treatment of BACTERIAL CONJUNCTIVITIS.
gatifloxacin : A monocarboxylic acid that is 4-oxo-1,4-dihydroquinoline-3-carboxylic acid which is substituted on the nitrogen by a cyclopropyl group and at positions 6, 7, and 8 by fluoro, 3-methylpiperazin-1-yl, and methoxy groups, respectively. Gatifloxacin is an antibiotic of the fourth-generation fluoroquinolone family, that like other members of that family, inhibits the bacterial topoisomerase type-II enzymes.
Body Weight: The mass or quantity of heaviness of an individual. It is expressed by units of pounds or kilograms.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The effects of age on gatifloxacin pharmacokinetic values were largely attributed to declining renal function, whereas those of gender were largely attributed to differences in body weight." | 3.70 | Age and gender effects on the pharmacokinetics of gatifloxacin. ( Behr, D; Duncan, G; Grasela, DM; Kollia, GD; LaCreta, FP, 2000) |
| " Pharmacokinetic parameters were estimated by fitting appropriate models to the serum concentration-time data using ADAPT II." | 2.72 | Gatifloxacin pharmacokinetics in healthy men and women. ( Kays, MB; Overholser, BR; Sowinski, KM; Zhang, X, 2006) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 2 (66.67) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Piubello, A | 1 |
| Harouna, SH | 1 |
| Souleymane, MB | 1 |
| Boukary, I | 1 |
| Morou, S | 1 |
| Daouda, M | 1 |
| Hanki, Y | 1 |
| Van Deun, A | 1 |
| Zhang, X | 1 |
| Overholser, BR | 1 |
| Kays, MB | 1 |
| Sowinski, KM | 1 |
| LaCreta, FP | 1 |
| Kollia, GD | 1 |
| Duncan, G | 1 |
| Behr, D | 1 |
| Grasela, DM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Culture Free Diagnosis and Follow-up of Multidrug Resistant Tuberculosis Patients[NCT03303963] | 3,356 participants (Actual) | Observational | 2017-05-04 | Completed | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 trial available for gatifloxacin and Body Weight
| Article | Year |
|---|---|
Gatifloxacin pharmacokinetics in healthy men and women.
Topics: Administration, Oral; Adult; Anti-Infective Agents; Area Under Curve; Body Weight; Chromatography, H | 2006 |
2 other studies available for gatifloxacin and Body Weight
| Article | Year |
|---|---|
High cure rate with standardised short-course multidrug-resistant tuberculosis treatment in Niger: no relapses.
Topics: Adolescent; Adult; Aged; Body Mass Index; Body Weight; Clofazimine; Dose-Response Relationship, Drug | 2014 |
Age and gender effects on the pharmacokinetics of gatifloxacin.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Anti-Infective Agents; Body Weight; Female; Fluoroquino | 2000 |